FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016165697> ?p ?o ?g. }

• W2016165697 abstract "Chronic obstructive pulmonary disease (COPD), is a very common disease of respiratory system. An increasing number of clinical trials on Yupingfeng formula in the management of stable COPD have been performed. However, the evidence base for it remains unknown. This review aims at assessing the efficacy, and safety of modified Yupingfeng formula in the treatment of stable COPD through a systematic review of all available randomized controlled trials.Literature retrieval was conducted using four English databases (CENTRAL, PubMed, EMBASE, and ISI Web of Science), and four Chinese databases (CBM, CNKI, VIP, and WANFANG), from respective inception to January 2013, and supplemented with a manual search. Review authors independently extracted the trial data, and assessed the quality of each trial. Methodological quality was assessed by Cochrane risk of bias and Jadad's scale. The following outcomes were evaluated: (1) lung function; (2) 6-minute walk distance (6MWD); (3) effective rate; (4) serum levels of IgA, IgG and IgE; and (5) adverse events. Data were analyzed using STATA 12.0 software.A total of nine studies involving 660, stable COPD patients were identified. Patients from all studies included in this review were randomized to receive Yupingfeng formula combined with Western medications in comparison with Western medications. In general, the methodological quality of the included trials was poor. The results of this systematic review indicates that, compared with Western medications alone, the use of Yupingfeng formula, if combined with Western medications could significantly improve FEV1 (WMD = 0.30L; 95%CI: 0.19, 0.42), FEV1/FVC ratio (SMD = 0.69; 95%CI: 0.48, 0.91), 6MWD (WMD = 31.73m; 95% CI: 19.29, 44.17), and effective rate (RR = 1.24; 95% CI: 1.10, 1.41), and increase the serum levels of IgA (WMD = 0.25; 95%CI: 0.16, 0.34) and IgG (WMD = 1.10; 95%CI: 0.53, 1.68), but no difference was found in the serum IgE levels (WMD = 0.47; 95%CI: -0.32, 1.27) between the two groups. No serious adverse events were reported.Within the limitations of this systematic review, we may conclude that compared with Western medications alone, Yupingfeng formula, when combined with Western medications can provide more benefits for patients with stable COPD, without any serious adverse reactions being identified. However, these benefits need to be further confirmed through high-quality prospective placebo-controlled trials that should be strictly conducted in accordance with methodological principles and procedures." @default.
• W2016165697 created "2016-06-24" @default.
• W2016165697 creator A5004478062 @default.
• W2016165697 creator A5028946960 @default.
• W2016165697 creator A5040327147 @default.
• W2016165697 creator A5045328432 @default.
• W2016165697 creator A5059291245 @default.
• W2016165697 creator A5076790638 @default.
• W2016165697 creator A5087122988 @default.
• W2016165697 creator A5089309949 @default.
• W2016165697 creator A5090625691 @default.
• W2016165697 date "2013-11-12" @default.
• W2016165697 modified "2023-10-15" @default.
• W2016165697 title "Modified yupingfeng formula for the treatment of stable chronic obstructive pulmonary disease: a systematic review of randomized controlled trials" @default.
• W2016165697 cites W1965199489 @default.
• W2016165697 cites W1976205692 @default.
• W2016165697 cites W1986215651 @default.
• W2016165697 cites W1989553188 @default.
• W2016165697 cites W2001075594 @default.
• W2016165697 cites W2001801035 @default.
• W2016165697 cites W2024265824 @default.
• W2016165697 cites W2025001606 @default.
• W2016165697 cites W2029044572 @default.
• W2016165697 cites W2049509720 @default.
• W2016165697 cites W2050344623 @default.
• W2016165697 cites W2053010637 @default.
• W2016165697 cites W2056130661 @default.
• W2016165697 cites W2075355273 @default.
• W2016165697 cites W2108696783 @default.
• W2016165697 cites W2127370507 @default.
• W2016165697 cites W2127951128 @default.
• W2016165697 cites W2146877487 @default.
• W2016165697 cites W2368875651 @default.
• W2016165697 cites W2381086697 @default.
• W2016165697 cites W2390703208 @default.
• W2016165697 cites W2398034655 @default.
• W2016165697 cites W2501346403 @default.
• W2016165697 cites W2952124176 @default.
• W2016165697 cites W9444414 @default.
• W2016165697 cites W2520162810 @default.
• W2016165697 doi "https://doi.org/10.4314/ajtcam.v11i1.1" @default.
• W2016165697 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3957235" @default.
• W2016165697 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24653547" @default.
• W2016165697 hasPublicationYear "2013" @default.
• W2016165697 type Work @default.
• W2016165697 sameAs 2016165697 @default.
• W2016165697 citedByCount "5" @default.
• W2016165697 countsByYear W20161656972016 @default.
• W2016165697 countsByYear W20161656972017 @default.
• W2016165697 countsByYear W20161656972018 @default.
• W2016165697 countsByYear W20161656972019 @default.
• W2016165697 countsByYear W20161656972021 @default.
• W2016165697 crossrefType "journal-article" @default.
• W2016165697 hasAuthorship W2016165697A5004478062 @default.
• W2016165697 hasAuthorship W2016165697A5028946960 @default.
• W2016165697 hasAuthorship W2016165697A5040327147 @default.
• W2016165697 hasAuthorship W2016165697A5045328432 @default.
• W2016165697 hasAuthorship W2016165697A5059291245 @default.
• W2016165697 hasAuthorship W2016165697A5076790638 @default.
• W2016165697 hasAuthorship W2016165697A5087122988 @default.
• W2016165697 hasAuthorship W2016165697A5089309949 @default.
• W2016165697 hasAuthorship W2016165697A5090625691 @default.
• W2016165697 hasBestOaLocation W20161656971 @default.
• W2016165697 hasConcept C126322002 @default.
• W2016165697 hasConcept C136524200 @default.
• W2016165697 hasConcept C168563851 @default.
• W2016165697 hasConcept C17744445 @default.
• W2016165697 hasConcept C177713679 @default.
• W2016165697 hasConcept C1862650 @default.
• W2016165697 hasConcept C189708586 @default.
• W2016165697 hasConcept C197934379 @default.
• W2016165697 hasConcept C199539241 @default.
• W2016165697 hasConcept C2776478404 @default.
• W2016165697 hasConcept C2776780178 @default.
• W2016165697 hasConcept C2779473830 @default.
• W2016165697 hasConcept C2992779976 @default.
• W2016165697 hasConcept C535046627 @default.
• W2016165697 hasConcept C71924100 @default.
• W2016165697 hasConcept C75603125 @default.
• W2016165697 hasConcept C95190672 @default.
• W2016165697 hasConceptScore W2016165697C126322002 @default.
• W2016165697 hasConceptScore W2016165697C136524200 @default.
• W2016165697 hasConceptScore W2016165697C168563851 @default.
• W2016165697 hasConceptScore W2016165697C17744445 @default.
• W2016165697 hasConceptScore W2016165697C177713679 @default.
• W2016165697 hasConceptScore W2016165697C1862650 @default.
• W2016165697 hasConceptScore W2016165697C189708586 @default.
• W2016165697 hasConceptScore W2016165697C197934379 @default.
• W2016165697 hasConceptScore W2016165697C199539241 @default.
• W2016165697 hasConceptScore W2016165697C2776478404 @default.
• W2016165697 hasConceptScore W2016165697C2776780178 @default.
• W2016165697 hasConceptScore W2016165697C2779473830 @default.
• W2016165697 hasConceptScore W2016165697C2992779976 @default.
• W2016165697 hasConceptScore W2016165697C535046627 @default.
• W2016165697 hasConceptScore W2016165697C71924100 @default.
• W2016165697 hasConceptScore W2016165697C75603125 @default.
• W2016165697 hasConceptScore W2016165697C95190672 @default.
• W2016165697 hasIssue "1" @default.
• W2016165697 hasLocation W20161656971 @default.
• W2016165697 hasLocation W20161656972 @default.

• next